Progress bias versus status quo bias in the ethics of emerging science and technology.


Journal

Bioethics
ISSN: 1467-8519
Titre abrégé: Bioethics
Pays: England
ID NLM: 8704792

Informations de publication

Date de publication:
03 2020
Historique:
received: 29 05 2018
revised: 02 04 2019
accepted: 18 04 2019
pubmed: 17 10 2019
medline: 2 10 2020
entrez: 17 10 2019
Statut: ppublish

Résumé

How should we handle ethical issues related to emerging science and technology in a rational way? This is a crucial issue in our time. On the one hand, there is great optimism with respect to technology. On the other, there is pessimism. As both perspectives are based on scarce evidence, they may appear speculative and irrational. Against the pessimistic perspective to emerging technology, it has been forcefully argued that there is a status quo bias (SQB) fuelling irrational attitudes to emergent science and technology and greatly hampering useful development and implementation. Therefore, this article starts by analysing the SQB using human enhancement as a case study. It reveals that SQB may not be as prominent in restricting the implementation of emergent technologies as claimed in the ethics literature, because SQB (a) is fuelled by other and weaker drivers than those addressed in the literature, (b) is at best one amongst many drivers of attitudes towards emergent science and technology, and (c) may not be a particularly prominent driver of irrational decision-making. While recognizing that SQB can be one driver behind pessimism, this article investigates other and counteracting forces that may be as strong as SQB. Progress bias is suggested as a generic term for the various drivers of unwarranted science and technology optimism. Based on this analysis, a test for avoiding or reducing this progress bias is proposed. Accordingly, we should recognize and avoid a broad range of biases in the assessment of emerging and existing science and technology in order to promote an open and transparent deliberation.

Identifiants

pubmed: 31617222
doi: 10.1111/bioe.12622
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

252-263

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Auteurs

Bjørn Hofmann (B)

Department of Health Sciences, Norwegian University of Science and Technology, Gjøvik, Norway.
Centre of Medical Ethics, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH